PHAXIAM Therapeutics Ownership 2024 | Who Owns PHAXIAM Therapeutics Now?
Institutional Ownership
0.44%
Institutional Holders
10.00
PHAXIAM Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| IKARIAN CAPITAL, LLC | 28.69% | 0.06% | 248,426 | 245,407 | 8128.75% | 252,111,000 | Mar 31, 2023 |
| MILLENNIUM MANAGEMENT LLC | 3.56% | - | 30,802 | 30,802 | 100.00% | 30,000 | Mar 31, 2023 |
| VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | 2.80% | 0.00% | 24,271 | -30,568 | -55.74% | 23,786,000 | Mar 31, 2023 |
| MARINER, LLC | 2.76% | 0.00% | 23,904 | -30,568 | -56.12% | 23,000 | Mar 31, 2023 |
| VIRTU FINANCIAL LLC | 2.31% | 0.00% | 20,026 | 20,026 | 100.00% | 20,000 | Mar 31, 2023 |
| CITADEL ADVISORS LLC | 1.25% | - | 10,807 | -26,782 | -71.25% | 10,591,000 | Mar 31, 2023 |
| GROUP ONE TRADING, L.P. | 1.22% | - | 10,590 | - | - | 10,378,000 | Mar 31, 2023 |
| ASSET DEDICATION, LLC | 0.46% | 0.00% | 4,000 | - | - | 4,000 | Mar 31, 2023 |
| UBS GROUP AG | 0.06% | - | 550 | -4,205 | -88.43% | 539,000 | Mar 31, 2023 |
| CITADEL ADVISORS LLC | 0.05% | - | 400 | 100 | 33.33% | 392,000 | Mar 31, 2023 |
| CITADEL ADVISORS LLC | 0.01% | - | 100 | 100 | 100.00% | 98,000 | Mar 31, 2023 |
| JEFFERIES FINANCIAL GROUP INC. | - | - | - | -572,698 | -100.00% | - | Mar 31, 2023 |
| OLD MISSION CAPITAL LLC | - | - | - | -9,083 | -100.00% | - | Mar 31, 2023 |
PHAXIAM Therapeutics's largest institutional shareholder is IKARIAN CAPITAL, LLC, holding 28.69% of the company's total share outstanding, currently valued at $252.11M. The top 10 institutional shareholders own together 43.17% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| IKARIAN CAPITAL, LLC | 28.69% | 0.06% | 248,426 | 245,407 | 8128.75% | 252,111,000 | Mar 31, 2023 |
| VIRTU FINANCIAL LLC | 2.31% | 0.00% | 20,026 | 20,026 | 100.00% | 20,000 | Mar 31, 2023 |
| VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | 2.80% | 0.00% | 24,271 | -30,568 | -55.74% | 23,786,000 | Mar 31, 2023 |
| ASSET DEDICATION, LLC | 0.46% | 0.00% | 4,000 | - | - | 4,000 | Mar 31, 2023 |
| MARINER, LLC | 2.76% | 0.00% | 23,904 | -30,568 | -56.12% | 23,000 | Mar 31, 2023 |
| GROUP ONE TRADING, L.P. | 1.22% | - | 10,590 | - | - | 10,378,000 | Mar 31, 2023 |
| MILLENNIUM MANAGEMENT LLC | 3.56% | - | 30,802 | 30,802 | 100.00% | 30,000 | Mar 31, 2023 |
| CITADEL ADVISORS LLC | 1.25% | - | 10,807 | -26,782 | -71.25% | 10,591,000 | Mar 31, 2023 |
| UBS GROUP AG | 0.06% | - | 550 | -4,205 | -88.43% | 539,000 | Mar 31, 2023 |
| CITADEL ADVISORS LLC | 0.05% | - | 400 | 100 | 33.33% | 392,000 | Mar 31, 2023 |
| CITADEL ADVISORS LLC | 0.01% | - | 100 | 100 | 100.00% | 98,000 | Mar 31, 2023 |
| JEFFERIES FINANCIAL GROUP INC. | - | - | - | -572,698 | -100.00% | - | Mar 31, 2023 |
| OLD MISSION CAPITAL LLC | - | - | - | -9,083 | -100.00% | - | Mar 31, 2023 |
The largest PHAXIAM Therapeutics shareholder by % of total assets is IKARIAN CAPITAL, LLC. The company owns 248.43K shares of PHAXIAM Therapeutics (ERYP), representing 0.06% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| IKARIAN CAPITAL, LLC | 28.69% | 0.06% | 248,426 | 245,407 | 8128.75% | 252,111,000 | Mar 31, 2023 |
| MILLENNIUM MANAGEMENT LLC | 3.56% | - | 30,802 | 30,802 | 100.00% | 30,000 | Mar 31, 2023 |
| VIRTU FINANCIAL LLC | 2.31% | 0.00% | 20,026 | 20,026 | 100.00% | 20,000 | Mar 31, 2023 |
| CITADEL ADVISORS LLC | 0.01% | - | 100 | 100 | 100.00% | 98,000 | Mar 31, 2023 |
| CITADEL ADVISORS LLC | 0.05% | - | 400 | 100 | 33.33% | 392,000 | Mar 31, 2023 |
| GROUP ONE TRADING, L.P. | 1.22% | - | 10,590 | - | - | 10,378,000 | Mar 31, 2023 |
| ASSET DEDICATION, LLC | 0.46% | 0.00% | 4,000 | - | - | 4,000 | Mar 31, 2023 |
| UBS GROUP AG | 0.06% | - | 550 | -4,205 | -88.43% | 539,000 | Mar 31, 2023 |
| OLD MISSION CAPITAL LLC | - | - | - | -9,083 | -100.00% | - | Mar 31, 2023 |
| CITADEL ADVISORS LLC | 1.25% | - | 10,807 | -26,782 | -71.25% | 10,591,000 | Mar 31, 2023 |
| MARINER, LLC | 2.76% | 0.00% | 23,904 | -30,568 | -56.12% | 23,000 | Mar 31, 2023 |
| VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | 2.80% | 0.00% | 24,271 | -30,568 | -55.74% | 23,786,000 | Mar 31, 2023 |
| JEFFERIES FINANCIAL GROUP INC. | - | - | - | -572,698 | -100.00% | - | Mar 31, 2023 |
As of Mar 31 2023, PHAXIAM Therapeutics's largest institutional buyer is IKARIAN CAPITAL, LLC. The company purchased 245.41K stocks of ERYP, valued at $252.11M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| JEFFERIES FINANCIAL GROUP INC. | - | - | - | -572,698 | -100.00% | - | Mar 31, 2023 |
| VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | 2.80% | 0.00% | 24,271 | -30,568 | -55.74% | 23,786,000 | Mar 31, 2023 |
| MARINER, LLC | 2.76% | 0.00% | 23,904 | -30,568 | -56.12% | 23,000 | Mar 31, 2023 |
| CITADEL ADVISORS LLC | 1.25% | - | 10,807 | -26,782 | -71.25% | 10,591,000 | Mar 31, 2023 |
| OLD MISSION CAPITAL LLC | - | - | - | -9,083 | -100.00% | - | Mar 31, 2023 |
| UBS GROUP AG | 0.06% | - | 550 | -4,205 | -88.43% | 539,000 | Mar 31, 2023 |
| ASSET DEDICATION, LLC | 0.46% | 0.00% | 4,000 | - | - | 4,000 | Mar 31, 2023 |
| GROUP ONE TRADING, L.P. | 1.22% | - | 10,590 | - | - | 10,378,000 | Mar 31, 2023 |
| CITADEL ADVISORS LLC | 0.05% | - | 400 | 100 | 33.33% | 392,000 | Mar 31, 2023 |
| CITADEL ADVISORS LLC | 0.01% | - | 100 | 100 | 100.00% | 98,000 | Mar 31, 2023 |
| VIRTU FINANCIAL LLC | 2.31% | 0.00% | 20,026 | 20,026 | 100.00% | 20,000 | Mar 31, 2023 |
| MILLENNIUM MANAGEMENT LLC | 3.56% | - | 30,802 | 30,802 | 100.00% | 30,000 | Mar 31, 2023 |
| IKARIAN CAPITAL, LLC | 28.69% | 0.06% | 248,426 | 245,407 | 8128.75% | 252,111,000 | Mar 31, 2023 |
As of Mar 31 2023, PHAXIAM Therapeutics's biggest institutional seller is JEFFERIES FINANCIAL GROUP INC.. The company sold -0.57M shares of ERYP, valued at -.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | 3.56% | - | 30,802 | 30,802 | 100.00% | 30,000 | Mar 31, 2023 |
| VIRTU FINANCIAL LLC | 2.31% | 0.00% | 20,026 | 20,026 | 100.00% | 20,000 | Mar 31, 2023 |
| CITADEL ADVISORS LLC | 0.01% | - | 100 | 100 | 100.00% | 98,000 | Mar 31, 2023 |
PHAXIAM Therapeutics's largest new institutional shareholder by number of shares is MILLENNIUM MANAGEMENT LLC, purchased 30.80K shares, valued at $30.00K, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| JEFFERIES FINANCIAL GROUP INC. | - | - | - | -572,698 | -100.00% | - | Mar 31, 2023 |
| OLD MISSION CAPITAL LLC | - | - | - | -9,083 | -100.00% | - | Mar 31, 2023 |
PHAXIAM Therapeutics's largest sold out institutional shareholder by shares sold is JEFFERIES FINANCIAL GROUP INC., sold -0.57M shares, valued at -, as of undefined.
PHAXIAM Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| FIDELITY CONCORD STREET TRUST | 0.00% | 2,542 | - | - | Feb 29, 2024 |
PHAXIAM Therapeutics's largest mutual fund holder by % of total assets is "FIDELITY CONCORD STREET TRUST", owning 2.54K shares, compromising 0.00% of its total assets.
PHAXIAM Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 23 | 10 | -9.09% |
| 31 Mar, 23 | 11 | 10.00% |
| 31 Dec, 22 | 10 | 11.11% |
| 30 Sep, 22 | 9 | 12.50% |
| 30 Jun, 22 | 8 | 14.29% |
| 31 Mar, 22 | 7 | -36.36% |
| 31 Dec, 21 | 11 | 10.00% |
| 30 Sep, 21 | 10 | 150.00% |
| 30 Jun, 21 | 4 | 33.33% |
| 31 Mar, 21 | 3 | -25.00% |
| 31 Dec, 20 | 4 | 33.33% |
| 30 Sep, 20 | 3 | -25.00% |
| 30 Jun, 20 | 4 | - |
| 31 Mar, 20 | 4 | - |
| 31 Dec, 19 | 4 | -20.00% |
| 30 Sep, 19 | 5 | - |
| 30 Jun, 19 | 5 | - |
| 31 Mar, 19 | 5 | - |
| 31 Dec, 18 | 5 | -37.50% |
| 30 Sep, 18 | 8 | 14.29% |
| 30 Jun, 18 | 7 | -12.50% |
| 31 Mar, 18 | 8 | -20.00% |
| 31 Dec, 17 | 10 | - |
As of 30 Jun 23, 10 institutions are holding PHAXIAM Therapeutics's shares, representing a decrease of -9.09% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 23 | 135,763 | -63.64% |
| 31 Mar, 23 | 373,376 | -50.29% |
| 31 Dec, 22 | 751,045 | -49.43% |
| 30 Sep, 22 | 1,485,082 | -1.24% |
| 30 Jun, 22 | 1,503,746 | -55.14% |
| 31 Mar, 22 | 3,351,792 | -20.64% |
| 31 Dec, 21 | 4,223,322 | 109.97% |
| 30 Sep, 21 | 2,011,390 | 3.33% |
| 30 Jun, 21 | 1,946,556 | 54.32% |
| 31 Mar, 21 | 1,261,343 | 0.03% |
| 31 Dec, 20 | 1,260,926 | -0.35% |
| 30 Sep, 20 | 1,265,342 | -2.54% |
| 30 Jun, 20 | 1,298,293 | -2.77% |
| 31 Mar, 20 | 1,335,342 | - |
| 31 Dec, 19 | 1,335,342 | -8.25% |
| 30 Sep, 19 | 1,455,419 | -0.22% |
| 30 Jun, 19 | 1,458,619 | -0.28% |
| 31 Mar, 19 | 1,462,682 | -0.07% |
| 31 Dec, 18 | 1,463,682 | -44.37% |
| 30 Sep, 18 | 2,631,032 | -42.80% |
| 30 Jun, 18 | 4,599,557 | 0.57% |
| 31 Mar, 18 | 4,573,446 | -0.66% |
| 31 Dec, 17 | 4,603,787 | - |
PHAXIAM Therapeutics (ERYP) has 135.76K shares outstanding as of 30 Jun 23, down -63.64% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 23 | 0.44% | 30.20% |
| 31 Mar, 23 | 1.20% | 20.53% |
| 31 Dec, 22 | 2.42% | 10.56% |
| 30 Sep, 22 | 4.79% | 20.37% |
| 30 Jun, 22 | 4.85% | 4.15% |
| 31 Mar, 22 | 10.81% | 3.40% |
| 31 Dec, 21 | 17.83% | 24.73% |
| 30 Sep, 21 | 8.49% | 10.47% |
| 30 Jun, 21 | 9.00% | 26.45% |
| 31 Mar, 21 | 5.83% | 11.81% |
| 31 Dec, 20 | 7.03% | 14.13% |
| 30 Sep, 20 | 7.05% | 13.47% |
| 30 Jun, 20 | 7.24% | 13.06% |
| 31 Mar, 20 | 7.44% | 13.43% |
| 31 Dec, 19 | 7.44% | 11.31% |
| 30 Sep, 19 | 8.11% | 12.27% |
| 30 Jun, 19 | 8.13% | 12.23% |
| 31 Mar, 19 | 8.15% | 12.25% |
| 31 Dec, 18 | 8.16% | 3.79% |
| 30 Sep, 18 | 14.67% | 2.23% |
| 30 Jun, 18 | 25.64% | 3.94% |
| 31 Mar, 18 | 25.50% | 3.87% |
| 31 Dec, 17 | 25.67% | - |
As of 30 Jun 23, PHAXIAM Therapeutics is held by 0.44% institutional shareholders, representing a 30.20% growth compared to 31 Mar 23.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 23 | 3 | - |
| 31 Mar, 23 | 3 | -25.00% |
| 31 Dec, 22 | 4 | 33.33% |
| 30 Sep, 22 | 3 | -25.00% |
| 30 Jun, 22 | 4 | 300.00% |
| 31 Mar, 22 | 1 | -87.50% |
| 31 Dec, 21 | 8 | 33.33% |
| 30 Sep, 21 | 6 | 100.00% |
| 30 Jun, 21 | 3 | 200.00% |
| 31 Mar, 21 | 1 | - |
| 31 Dec, 20 | 1 | - |
| 30 Sep, 20 | - | - |
| 30 Jun, 20 | - | - |
| 31 Mar, 20 | - | - |
| 31 Dec, 19 | - | -100.00% |
| 30 Sep, 19 | 1 | - |
| 30 Jun, 19 | - | - |
| 31 Mar, 19 | - | - |
| 31 Dec, 18 | - | -100.00% |
| 30 Sep, 18 | 2 | 100.00% |
| 30 Jun, 18 | 1 | - |
| 31 Mar, 18 | - | -100.00% |
| 31 Dec, 17 | 10 | - |
3 institutional shareholders have increased their position in ERYP stock as of 30 Jun 23 compared to 3 in the previous quarter (a 0.00% increase).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 23 | 2 | -50.00% |
| 31 Mar, 23 | 4 | 100.00% |
| 31 Dec, 22 | 2 | -50.00% |
| 30 Sep, 22 | 4 | 100.00% |
| 30 Jun, 22 | 2 | -50.00% |
| 31 Mar, 22 | 4 | - |
| 31 Dec, 21 | - | -100.00% |
| 30 Sep, 21 | 1 | - |
| 30 Jun, 21 | - | - |
| 31 Mar, 21 | - | -100.00% |
| 31 Dec, 20 | 1 | - |
| 30 Sep, 20 | - | -100.00% |
| 30 Jun, 20 | 1 | - |
| 31 Mar, 20 | - | -100.00% |
| 31 Dec, 19 | 1 | -50.00% |
| 30 Sep, 19 | 2 | - |
| 30 Jun, 19 | 2 | 100.00% |
| 31 Mar, 19 | 1 | - |
| 31 Dec, 18 | 1 | -66.67% |
| 30 Sep, 18 | 3 | - |
| 30 Jun, 18 | 3 | 50.00% |
| 31 Mar, 18 | 2 | - |
| 31 Dec, 17 | - | - |
2 institutional shareholders have reduced their position in ERYP stock as of 30 Jun 23 compared to 4 in the previous quarter (a -50.00% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 23 | 10 | -9.09% | 135,763 | -63.64% | 0.44% | 30.20% | 3 | - | 2 | -50.00% |
| 31 Mar, 23 | 11 | 10.00% | 373,376 | -50.29% | 1.20% | 20.53% | 3 | -25.00% | 4 | 100.00% |
| 31 Dec, 22 | 10 | 11.11% | 751,045 | -49.43% | 2.42% | 10.56% | 4 | 33.33% | 2 | -50.00% |
| 30 Sep, 22 | 9 | 12.50% | 1,485,082 | -1.24% | 4.79% | 20.37% | 3 | -25.00% | 4 | 100.00% |
| 30 Jun, 22 | 8 | 14.29% | 1,503,746 | -55.14% | 4.85% | 4.15% | 4 | 300.00% | 2 | -50.00% |
| 31 Mar, 22 | 7 | -36.36% | 3,351,792 | -20.64% | 10.81% | 3.40% | 1 | -87.50% | 4 | - |
| 31 Dec, 21 | 11 | 10.00% | 4,223,322 | 109.97% | 17.83% | 24.73% | 8 | 33.33% | - | -100.00% |
| 30 Sep, 21 | 10 | 150.00% | 2,011,390 | 3.33% | 8.49% | 10.47% | 6 | 100.00% | 1 | - |
| 30 Jun, 21 | 4 | 33.33% | 1,946,556 | 54.32% | 9.00% | 26.45% | 3 | 200.00% | - | - |
| 31 Mar, 21 | 3 | -25.00% | 1,261,343 | 0.03% | 5.83% | 11.81% | 1 | - | - | -100.00% |
| 31 Dec, 20 | 4 | 33.33% | 1,260,926 | -0.35% | 7.03% | 14.13% | 1 | - | 1 | - |
| 30 Sep, 20 | 3 | -25.00% | 1,265,342 | -2.54% | 7.05% | 13.47% | - | - | - | -100.00% |
| 30 Jun, 20 | 4 | - | 1,298,293 | -2.77% | 7.24% | 13.06% | - | - | 1 | - |
| 31 Mar, 20 | 4 | - | 1,335,342 | - | 7.44% | 13.43% | - | - | - | -100.00% |
| 31 Dec, 19 | 4 | -20.00% | 1,335,342 | -8.25% | 7.44% | 11.31% | - | -100.00% | 1 | -50.00% |
| 30 Sep, 19 | 5 | - | 1,455,419 | -0.22% | 8.11% | 12.27% | 1 | - | 2 | - |
| 30 Jun, 19 | 5 | - | 1,458,619 | -0.28% | 8.13% | 12.23% | - | - | 2 | 100.00% |
| 31 Mar, 19 | 5 | - | 1,462,682 | -0.07% | 8.15% | 12.25% | - | - | 1 | - |
| 31 Dec, 18 | 5 | -37.50% | 1,463,682 | -44.37% | 8.16% | 3.79% | - | -100.00% | 1 | -66.67% |
| 30 Sep, 18 | 8 | 14.29% | 2,631,032 | -42.80% | 14.67% | 2.23% | 2 | 100.00% | 3 | - |
| 30 Jun, 18 | 7 | -12.50% | 4,599,557 | 0.57% | 25.64% | 3.94% | 1 | - | 3 | 50.00% |
| 31 Mar, 18 | 8 | -20.00% | 4,573,446 | -0.66% | 25.50% | 3.87% | - | -100.00% | 2 | - |
| 31 Dec, 17 | 10 | - | 4,603,787 | - | 25.67% | - | 10 | - | - | - |
PHAXIAM Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| ENOB | Renovaro Biosciences Inc. |
| CYT | Cyteir Therapeutics, Inc. |
| NTRB | Nutriband Inc. |
| IKNA | Ikena Oncology, Inc. |
| XCUR | Exicure, Inc. |
| SRZN | Surrozen, Inc. |
| XRTX | XORTX Therapeutics Inc. |
| HCWB | HCW Biologics Inc. |
| SNGX | Soligenix, Inc. |
| GNFT | Genfit S.A. |
| UNCY | Unicycive Therapeutics, Inc. |
| ATXI | Avenue Therapeutics, Inc. |
| MOLN | Molecular Partners AG |
| ADXN | Addex Therapeutics Ltd |
| ELYM | Eliem Therapeutics, Inc. |
ERYP Ownership FAQ
Who Owns PHAXIAM Therapeutics?
PHAXIAM Therapeutics is owned by institutional shareholders (0.44%), insiders (0.00%), and public (99.56%). The largest institutional shareholder of PHAXIAM Therapeutics is IKARIAN CAPITAL, LLC (28.69% of total shares) and the top mutual fund owner is FIDELITY CONCORD STREET TRUST (0.00% of total shares).
Who are the major institutional shareholders of PHAXIAM Therapeutics?
PHAXIAM Therapeutics's major institutional shareholders are IKARIAN CAPITAL, LLC, MILLENNIUM MANAGEMENT LLC, VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC, MARINER, LLC, and VIRTU FINANCIAL LLC. The top five shareholders own together 40.13% of the company's share outstanding.
How many PHAXIAM Therapeutics shareholders are there?
As of Jun 2023, there are 10 institutional shareholders of PHAXIAM Therapeutics.
What percentage of PHAXIAM Therapeutics is owned by IKARIAN CAPITAL, LLC?
IKARIAN CAPITAL, LLC owns 248.43K shares of PHAXIAM Therapeutics, representing 28.69% of the company's total shares outstanding, valued at $252.11M (as of Mar 2023).
What percentage of PHAXIAM Therapeutics is owned by MILLENNIUM MANAGEMENT LLC?
As of Mar 2023, MILLENNIUM MANAGEMENT LLC holds 30.8K shares of PHAXIAM Therapeutics (ERYP), compromising 3.56% of the company, valued at $30K.
What percentage of PHAXIAM Therapeutics is owned by VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC?
VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC is the third largest holder of PHAXIAM Therapeutics. The company owns 24.27K of the company's shares outstanding (worth $23.79M).